Page 130 - Read Online

Shek et al. Cancer Drug Resist 2019;2:69-81 I http://dx.doi.org/10.20517/cdr.2018.20 Page 81

72. Lee SY, Jung DK, Choi JE, Jin CC, Hong MJ, et al. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer
patients treated with first-line paclitaxel-cisplatin chemotherapy. Sci Rep 2016;6:25952.
73. Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, et al. Influence of cytotoxic T lymphocyte-associated antigen 4
(CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 2008;31:586-
90.
74. Queirolo P, Morabito A, Laurent S, Lastraioli S, Piccioli P, et al. Association of CTLA-4 polymorphisms with improved overall survival
in melanoma patients treated with CTLA-4 blockade: a pilot study. Cancer Invest 2013;31:336-45.
75. Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, et al. Association of CTLA-4 gene variants with response to therapy and
long-term survival in metastatic melanoma patients treated with ipilimumab: an italian melanoma intergroup study. Front Immunol
2017;8:386.
76. Palacios R, Comas D, Elorza J, Villoslada P. Genomic regulation of CTLA4 and multiple sclerosis. J Neuroimmunol 2008;203:108-15.
77. Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, et al. CTLA-4 gene variant -1661A>G may predict the onset of endocrine
adverse events in metastatic melanoma patients treated with ipilimumab. Eur J Cancer 2018;97:59-61.
78. Kamps R, Brandao RD, Bosch BJ, Paulussen AD, Xanthoulea S, et al. Next-generation sequencing in oncology: genetic diagnosis, risk
prediction and cancer classification. Int J Mol Sci 2017;18:E308.
79. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, et al. Cancer immunology. Mutational landscape determines sensitivity to
PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.